LPS에 의해 자극된 RAW264.7 세포에 대한 계지가출부탕의 항염증활동

Abstract

Objectives GyejigaChulBuTang (GCBT) is a prescription used to treat acute and chronic arthritis in Korea, China, and Japan. This study assessed the anti-inflammatory and anti-oxidant activities of GCBT on lipopolysaccharide (LPS)-stimulated RAW264.7 macrophage cells. Methods Raw264.7 cells were pretreated with or without GCBT for 1 hour prior to incubation with LPS. Anti-inflammatory activity of GCBT was evaluated with reference to gene expression and production levels of proinflammatory cytokines (<TEX>$TNF{\alpha}$</TEX>, IL-<TEX>$1{\beta}$</TEX>, IL-6, GM-CSF and <TEX>$INF{\gamma}$</TEX>) and inflammatory mediators (iNOS, COX-2, NO and <TEX>$PGE_2$</TEX>). In addition, intracellular ROS generation and signal transduction of MAPK family, PI3K/Akt and <TEX>$I{\kappa}B{\alpha}/NF{\kappa}B$</TEX> was investigated. Results Prior treatment with GCBT inhibited elevation of <TEX>$TNF{\alpha}$</TEX>, IL-<TEX>$1{\beta}$</TEX>, IL-6, GM-CSF, <TEX>$INF{\gamma}$</TEX>, NO and <TEX>$PGE_2$</TEX>, together with their cognate mRNAs in a dose-dependent manner. Intracellular ROS contents were similarly reduced. These effects were due to inhibition of LPS-induced phosphorylation of MAPK family, PI3K/Akt and <TEX>$I{\kappa}B{\alpha}$</TEX> as well as nuclear translocation of <TEX>$NF{\kappa}B$</TEX>. Conclusions GCBT suppresses pro-inflammatory mediators. GCBT has potential in the treatment of juvenile rheumatoid arthritis associated with inflammation.